ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012
Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer.
Ugo De Giorgi et al.PubMed ↗Publisher ↗
No numbers read from the abstract.